ALK and neoplasm: Y5-3 features a disulphide (-S-S-) bond extended from the ALK-targeting PROTAC linker, conjugated to palbociclib (a CDK4/6 inhibitor), and cleaved by GSH to selectively release its functional moieties in tumour cells.